About 100 reports

Top 50 Biosimilar Drug Manufacturers 2021: Profiles of Top 50 Leading Biosimilar Companies and Forecasts by Product (Adalimumab, Etanercept, Trastuzumab, Infliximab, Insulin Glargine, Rituximab, Pegfilgrastim, Epoetin Alfa, Teriparatide, Bevacizumab, Insulin Lispro, Darbepoetin Alfa, Filgrastim, Enoxaparin, Eculizumab, Natalizumab,...

  • Biopharmaceutical
  • Monoclonal Antibody
  • Biosimilar
  • World
  • APAC

"Bevacizumab Biosimilar Market Opportunity, Sales, Price & Clinical Trials Insight 2025" Report Highlights: • Bevacizumab Market Opportunity: > USD 12 Billion by 2025 • Bevacizumab Biosimilar in Clinical Trials: > 25 Biosimilars • Bevacizumab Biosimilar Available in Market: >8 Biosimilars • Bevacizumab...

  • Biosimilar
  • Cancer
  • Monoclonal Antibody
  • World

Major players in the pegfilgrastim biosimilars market are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals and Fresenius Kabi. The global pegfilgrastim biosimilar market is expected to decline from $534.43 million in 2019 to $453.11 million in 2020 at a compound annual growth rate (CAGR) of -15.22%. The decline...

  • Biopharmaceutical
  • Monoclonal Antibody
  • Biosimilar
  • World
  • Spain
  • United Kingdom
  • Drug Approval

Global Biosimilar Monoclonal Antibodies Forecast 2020-2030: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab • Global Biosimilar Monoclonal Antibodies Market forecasts from 2017-2027 • Along with revenue prediction for the overall world market for biosimilar monoclonal...

  • Monoclonal Antibody
  • Biosimilar
  • World

Since 2009, 25 biosimilars of 12 originator products are approved in Japan and have yielded mixed performances and attained annual sales of ~¥32.4b ($300m). Unique biosimilars landscape with the entry of NESP “biosame” by originator Kyowa Hakko Kirin through its subsidiary, co-promotion/marketing collaboration with local companies for the...

  • Biopharmaceutical
  • Biosimilar
  • Japan
  • Biosimilar Penetration Rate
  • Biosimilar Approvals

"US Cancer Biosimilar Market Opportunity, Drug Dosage, Price & Clinical Trials Insight 2026" Report highlights: • US Cancer Biosimilar Market Opportunity: > US$ 15 Billion By 2026 • Currently 29 Cancer Biosimilar Approved In US Market • Pricing & Dosage Insight On More Than 10 Cancer Biosimilar Commercially Available...

  • Biosimilar
  • Therapy
  • United States
  • Mortality Rate
  • Biosimilar Approvals

Major players in the oral biologics and biosimilar market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd. and Allergan plc. The global oral biologics & biosimilar drugs market is expected to grow from $3.53 billion in 2020 to...

  • Biopharmaceutical
  • Biosimilar
  • World
  • Biosimilar Approvals
  • Chronic Disease Prevalence

In this research service, the Transformational Health team provides critical insights into the global biosimilar industry, highlighting the key growth opportunities, market revenue forecasts, and trends that will influence the industry with the emergence of the third wave of biosimilars. The global third-wave biosimilars market covered in...

  • Biopharmaceutical
  • Biosimilar
  • World
  • Biosimilar Penetration Rate
  • Biologics Patents Registrations

Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline (GSK), Novartis AG and Novo Nordisk A/S. The global biosimilar therapeutic peptides market is expected to decline from $0.80 billion in 2019 to $0.77...

  • Biosimilar
  • Chronic Disease
  • Drug Development
  • Biotechnology
  • Therapy
  • World
  • United Kingdom
  • Drug Approval
  • Biosimilar Sales

Biosimilar Growth Hormones Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global biosimilar growth hormones market. This report focuses on biosimilar growth hormones market which is experiencing strong growth. The...

  • Biosimilar
  • World

CRO Regulatory Services for Generics and Biosimilars Drugs Market Report 2020-2030: Forecasts by Services (Regulatory Writing and Publishing, Clinical Trial Application and Product Registration, Regulatory Consulting, Legal Representation, and Other Regulatory Services analyses), by Application (Oncology, Cardiology, Infectious Diseases,...

  • Biosimilar
  • World
  • APAC
  • Europe
  • Latin America
  • Middle East
  • Africa

GLOBAL BIOSIMILARS MARKET

  • Biosimilar
  • Monoclonal Antibody
  • Autoimmune Disease
  • Drug Development
  • World
  • APAC
  • Biosimilar Penetration Rate
  • Biosimilar Approvals

Biosimilars Market - Scope of the Report This report on the global biosimilars market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market during the forecast period of 2019 to 2027.The report provides the overall market revenue...

  • Biosimilar
  • Healthcare
  • World

Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietins, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones The global biosimilars and follow-on biologics market is estimated to have reached $10.7bn in 2018 and expected to grow at a CAGR of 5.4% in the first...

  • Biosimilar
  • World
  • Cancer Incidence

Europe Biosimilar Insulin Glargine & Lispro Market, By End User (Type 1 Diabetes and Type 2 Diabetes),By Country (Germany, United Kingdom, France, Italy, Spain, Russia, Turkey, Poland, The Netherlands, Austria & Rest of Europe), Competition, Forecast & Opportunities, 2024 Europe biosimilar insulin glargine and lispro...

  • Biosimilar
  • Europe

Asia Pacific Biosimilar Insulin Glargine & Lispro Market, By End User (Type 1 Diabetes and Type 2 Diabetes), By Country (Japan, China, India, South Korea, Bangladesh, Pakistan), Competition, Forecast & Opportunities, 2024 Biosimilar is a biological product which is similar to the reference product, already approved...

  • Biosimilar
  • APAC
  • Biosimilar Sales
  • Overweight Prevalence

"US Biosimilars Market, Dosage, Price & Clinical Pipeline Outlook 2025" Report Highlights: US Biosimilar Market Current ScenarioUS Biosimilars Clinical Pipeline by Company, Indication & Phase: 28 BiosimilarsMarketed Biosimilars...

  • Biopharmaceutical
  • Biosimilar
  • United States
  • Biosimilar Penetration Rate
  • Biosimilar Approvals

Biosimilars in India

  • Biosimilar
  • World
  • Biosimilar Approvals
  • Biosimilar Penetration Rate

The biosimilar market in Europe reached a value of US$ 2,934.6 Million in 2018. The market is further projected to reach a value of US$ 11,663.1 Million by 2024, growing at a CAGR of 24.9% during 2019-2024. The European biosimilar market represents the most mature in the world and continues to rally momentum. This market is expected to grow...

  • Biosimilar
  • Europe
  • Biosimilar Approvals

##. The Biosimilar Pipeline

  • Biosimilar
  • Drug Development
  • United States
  • European Union
  • Indiana
  • Biosimilar Approvals
  • Biosimilar Penetration Rate

Global Biosimilar Monoclonal Antibodies (mAbs) Market 2020-2024 The analyst has been monitoring the biosimilar monoclonal antibodies (mAbs) market and it is poised to grow by $ 8.65 bn during 2020-2024 progressing at a CAGR of 30% during the forecast period. Our reports on biosimilar monoclonal antibodies (mAbs) market...

  • Monoclonal Antibody
  • Biosimilar
  • World
  • Chronic Disease Prevalence

About this market Patients and physician’s willingness to switch to biosimilars is expected to drive growth in the market. Majority of physicians, especially rheumatologists, preferred to prescribe a bio-originator instead of biosimilar as the first line therapy for the treatment. However, the physician and patients...

  • Health Care Provider
  • Healthcare
  • Biosimilar
  • Clinical Trial
  • World

Report Includes: - An overview of top five opportunities for generic or biosimilar drugs in pharmaceuticals market 2019 - Coverage of generics and discussion on their characteristics - Information on Hatchmann-Wax act and its effect on market competitiveness impacting pricing and development of original drugs -...

  • Pharmaceutical
  • Generic Drug
  • Biosimilar
  • World

Biosimilar Regulatory Pathways

  • Biosimilar
  • United States
  • India
  • Japan
  • South Korea
  • Biosimilar Penetration Rate
  • Biologics Penetration Rate

Major players in the filgrastim biosimilars market are Cadila Pharmaceuticals, Dr. Reddy’s Laboratories, Intas Biopharmaceuticals, Sandoz, Amgen Inc., Dr. Reddy’s Laboratories Ltd, Intas Pharmaceuticals, Emcure Pharmaceuticals Ltd., Biocon and Aryogen Biopharma. The global filgrastim biosimilars market is expected to decline from $511.15...

  • Biosimilar
  • World
  • United States
  • Biosimilar Approvals
  • Biosimilar Penetration Rate

Filgrastim Biosimilars Market Trends And Strategies

  • Biosimilar
  • World
  • APAC
  • Disposable Income
  • Health Expenditure

Major players in the parathyroid hormone market are Pfizer Inc, Eli Lilly and Company, Radius Health Inc, Shire, Ascendis Pharma, Entera Bio Ltd. and Extend Biosciences, Inc. The global parathyroid hormone market is expected to decline from $1.78 billion in 2019 to $1.70 billion in 2020 at a compound annual growth rate (CAGR) of -4.4%....

  • Pharmaceutical
  • Musculoskeletal Disorder
  • Biosimilar
  • World
  • United States
  • Europe

What Is a Biosimilar?

  • Biosimilar
  • India
  • United States
  • South Korea
  • Japan
  • Biosimilar Penetration Rate
  • Biosimilar Approvals

Report Scope: Biosimilars are replicas of the innovator biopharmaceuticals.They offer the advantage of being less expensive as compared to their expensive counterparts. The structural and manufacturing complexities associated with their development have led to extensive approval guidelines and regulations by the...

  • Biopharmaceutical
  • Biosimilar
  • World
  • Biosimilar Approvals
  • Health Expenditure

The biosimilar market reached a value of US$ 2.9 Billion in 2017. This market is currently being driven by a number of factors such as patent expires of blockbuster biological drugs, lower prices, rising prevalence of chronic diseases, and cost saving initiatives from governments and third party payers. Catalyzed by these factors, the market...

  • Biopharmaceutical
  • Biosimilar
  • World
  • Chronic Disease Prevalence
  • Biosimilar Penetration Rate